A B S T R A C T To determine the relationship between platelet secretion and prothrombin conversion in whole blood, the release ofplatelet factor 4 and the generation of a Xa-specific cleavage product of prothrombin, fragment 1 + 2, were measured during the coagulation of whole blood. There was a parallel increase in the concentration of the two proteins. Over the first 5 min of incubation, platelet factor 4 concentration increased 6 ng/ml per min, and after 6-7 min, the rate of release increased to 750 ng/ml per min. Over the initial 5-7 min ofincubation, fragment 1 + 2 concentration increased 1.5 pmol/ml per min with a subsequent increase of 45 pmol/ml per min. Incubation with 10 ,uM prostaglandin E, or 15 ,uM prostaglandin I2 inhibited secretion of platelet factor 4 and delayed the onset of the rapid phase of fragment 1 + 2 generation by 8 min, while stimulation of platelet secretion with 1 ,tg/ml collagen suspension enhanced production of fragment 1 + 2. The addition of either 10 ,uM epinephrine or 100 ng/ml collagen suspension to whole blood did not affect either platelet factor 4 release or fragment 1 + 2 generation, although the combination of 3 IuM epinephrine and 100 ng/ml collagen suspension enhanced platelet release and prothrombin cleavage.
A B S T R A C T To determine the relationship between platelet secretion and prothrombin conversion in whole blood, the release ofplatelet factor 4 and the generation of a Xa-specific cleavage product of prothrombin, fragment 1 + 2, were measured during the coagulation of whole blood. There was a parallel increase in the concentration of the two proteins. Over the first 5 min of incubation, platelet factor 4 concentration increased 6 ng/ml per min, and after [6] [7] min, the rate of release increased to 750 ng/ml per min. Over the initial 5-7 min ofincubation, fragment 1 + 2 concentration increased 1.5 pmol/ml per min with a subsequent increase of 45 pmol/ml per min. Incubation with 10 ,uM prostaglandin E, or 15 ,uM prostaglandin I2 inhibited secretion of platelet factor 4 and delayed the onset of the rapid phase of fragment 1 + 2 generation by 8 min, while stimulation of platelet secretion with 1 ,tg/ml collagen suspension enhanced production of fragment 1 + 2. The addition of either 10 ,uM epinephrine or 100 ng/ml collagen suspension to whole blood did not affect either platelet factor 4 release or fragment 1 + 2 generation, although the combination of 3 IuM epinephrine and 100 ng/ml collagen suspension enhanced platelet release and prothrombin cleavage.
The relationship between platelet factor 4 release and prothrombin cleavage was also studied in Factor VIII-deficient blood. When 0.001 U/ml factor VIII activity was present, <80 ng/ml platelet factor 4 were released, and no fragment 1 + 2 was generated after 30 min of incubation. The addition of 0.008-0.08 U/ml Factor VIII activity progressively increased platelet factor 4 release and prothrombin cleavage. Platelet factor 4 release was normal at 0.08 U/ml Factor VIII activity, whereas prothrombin cleavage was still delayed. Very little thrombin, the amount generated by INTRODUCTION The ability of platelets to accelerate blood coagulation reactions, a property referred to as platelet factor 3 (PF-3) activity,' has been recognized for many years. The molecular basis for activity and the precise steps in the coagulation sequence that are accelerated by platelets are not yet fully understood. Studies using phospholipid micelles, purified Factor V, and prothrombin have convincingly demonstrated that at least one of the events in coagulation, prothrombin conversion, occurs more rapidly on a surface than in solution (1) . Recent experiments by Miletich et al. (2) (3) (4) have demonstrated that platelets can accelerate prothrombin conversion by binding Factor V, which, when activated to Va by thrombin, serves as a receptor for factor Xa. The binding of Xa to Va on the platelet surface markedly increases prothrombin conversion to thrombin (2, 3) . Subsequent studies have shown that either Factor V, present in platelet granules or plasma Factor V can serve as a source of V., and that the platelet membrane has a limited number of high-affinity V.
binding sites (2) (3) (4) (5) .
There are problems inherent in the design of these previous investigations, which have used either model lipid micelles or washed platelets and purified coagulation proteins. Although these studies accurately measure both binding to particles and subsequent enzymatic activity, they may not accurately reflect coagulation as it occurs in whole blood. For example, the relative importance of the platelet compared to other surfaces, or the source of Va, cannot be determined in purified systems. Reports that the severity of bleeding in patients with congenital Factor V deficiency may relate to platelet content of Factor V (6) , and the observation that patients with a platelet defect characterized by an inability to bind Va have a mild bleeding disorder, further strengthen the hypothesis that platelets regulate plasma prothrombin conversion (7). However, there have not yet been any direct measurements of prothrombin conversion in whole blood to confirm these indirect observations.
The development of radioimmunoassays for secreted platelet-specific proteins (8-10) and for activation peptides of the coagulation cascade (11, 12) now permits a direct correlation of events that occur before fibrin formation with platelet activation and secretion. Shuman and Levine (13) used such radioimmunoassay techniques to study the generation of thrombin during coagulation of native whole blood and were able to closely relate thrombin generation and platelet secretion. They concluded that platelet secretion required thrombin, but that inhibition of platelet release did not influence the rate of thrombin generation (13, 14) . Kaplan and co-workers (10), who added thrombin to washed platelet suspensions containing fibrinogen, or to citrated plasma, noted that the release of fibrinopeptide A, a thrombin-specific cleavage product, preceded platelet release of 8-thromboglobulin or platelet factor 4 (PF-4) and suggested that fibrinogen was the preferred substrate for exogenous thrombin.
The studies reported here were designed to specifically assess how platelets regulate prothrombin conversion in native whole blood. Radioimmunoassays were utilized to measure the secretion of PF-4, a plateletspecific a-granule protein, and the generation of prothrombin cleavage fragments F1+2 (F1+2). Our studies demonstrate a close linkage between prothrombin cleavage and platelet secretion in native whole blood and show that agonists which facilitate platelet release enhance prothrombin conversion, whereas inhibitors of platelet secretion retard prothrombin conversion. 
METHODS

RESULTS
Prothrombin cleavage and platelet secretion in normal whole blood. In a series of six experiments performed with native whole blood from normal volunteers, the generation ofthe Xa-specific cleavage product of prothrombin, F1+2, closely paralleled the secretion of As shown in Fig. 1 , the PF-4 concentration increased very little during the first 5 min of incubation but after 6-7 min, there was rapid release of PF4. In six experiments the transition to more rapid PF-4 secretion occurred after 6+1 min (x±SE) of incubation. When the PF-4 concentration reached 1,500-2,500 ng/ml, visible traces of clot appeared in the tubes, and sampling was discontinued.
The pattern ofF1+2 generation was quite similar. Dur- ing the initial 5-7 min of incubation, the F1+2 concentration increased slowly, followed by several minutes of more accelerated F1+2 generation. The acceleration of F1+2 generation coincided closely with the onset of rapid PF-4 release, with the phase of rapid F1+2 generation also occurring after 6±1 (x +SE) min of incubation (Fig. 1) . The amount of F2+2 generated at the moment of visible clot formation represented the cleavage of 5-6% of the available prothrombin in plasma. Similarly, the amount of PF-4 released represents only 15-20% of the total releasable PF-4. Inhibition and stimulation of platelet secretion: effect on prothrombin cleavage. As shown in Fig. 2 , prior treatment of donors with aspirin, which presumably blocked platelet prostaglandin/thromboxane production, did not change the pattern of PF-4 release and F1+2 generation. However, the addition of 10 ,uM PGE, to the blood before stirring delayed both the release of PF-4 and the generation of F1+2 (Fig. 1) .
In the tube containing PGE,, 19+11 ng/ml (x+SE) PF-4 had been released after 10 min of incubation compared with 888±218 ng/ml (i±SE) in the control tube. There was a similar delay in F1+2 generation. Although inhibition of the release reaction with PGE, did not retard F1+2 generation during the first 8 min of incubation, there was a delay in the onset of the more rapid phase of F1+2 production. For example, after 15 min incubation in the presence of PGE1, only 11± 1.36 nM (x±SE) F1+2 had been generated compared with 174±69.2 nM (i±SE) in the control tube at 10 min. The addition of PGI2 to whole blood every 3 min, in an attempt to maintain a plasma concentration of at least 15 ,uM PGI2, produced similar inhibition of prothrombin cleavage.
Stimulation of platelet secretion by collagen fibrils enhanced prothrombin cleavage (Fig. 1 ). The addition of 2 ,ug/ml collagen suspension raised the PF-4 concentration to 753±104 ng/ml (x± SE) after 5 min of incubation, compared with 17±1 ng/ml (x±SE) in the control tube. Maximum PF-4 release occurred at 6-7 min, compared with 10-12 min in the control tube. Collagen addition also decreased the time to the onset of rapid prothrombin cleavage, so that 36±13 nM (x±SE) F1+2 had been generated after 6 min incubation in the presence of collagen compared with 4 ± 1.5 nM (i±SE) in the control tube (P < 0.001). Although the time to rapid F1+2 generation was shortened 2 min by the addition of collagen, the time elapsed between enhanced platelet secretion and enhanced prothrombin cleavage was actually increased to an average of 6 min, demonstrating that platelet secretion and prothrombin cleavage could be disassociated.
In contrast to the results observed with collagen, the addition of 0.1-10 ,M epinephrine to native blood did not enhance either platelet release or F1+2 generation. These concentrations of epinephrine have been shown to elicit biphasic platelet aggregation in citrated PRP from the same donor (data not shown). However, epinephrine did accelerate platelet release and F1+2 generation in whole blood when added along with low concentrations of collagen (Fig. 3) . While the addition of either 0.1 1,g/ml collagen or 3 Epinephrine alone could induce platelet secretion of in whole blood anticoagulated with 3.8% sodium citrate, although the total quantity of PF-4 released in citrated blood was much less than in native blood in which thrombin was also being generated. For example, 8 ng/ml PF-4 were released at 15 min in citrated blood to which no additions were made, compared with 100 ng/ml released when 3 ,uM epinephrine was added.
Platelet secretion and prothrombin cleavage in Factor VIII-deficient blood. The results of experiments with blood from three patients with severe Factor VIII deficiency are shown in Fig. 4 . The absence ofthis plasma protein activity markedly reduced PF-4 release and F1+2 generation. After 60 min of incubation, only 80 ng/ml PF4 had been released, and 2 nM F1+2 had been generated. The addition of 1 gug/ml collagen caused full release of PF-4, with 450 ng/ml in plasma after 4 min of incubation. In contrast to normal individuals, stimulation of platelet secretion did not enhance F1+2 generation. The F1+2 concentration remained at 2 nM even after 45 min of incubation, and no visible clot appeared in any of the tubes. The addition of 6 ,uM epinephrine also did not affect PF-4 release in FactorVIII-deficient whole blood (not shown).
Partially purified human Factor VIII was added to samples of deficient blood to raise the functional VIII activity to <0.01, 0.04, and 0.08 U/ml, respectively. After inverting the tubes once, they were incubated and stirred along with a sample with no Factor VIII added. F1+2 generation and PF-4 secretion after the addition of Factor VIII are depicted in Fig. 5 . In the tube with no Factor VIII added, there was no change in the F1+2 concentration over the first 30 min of incubation with only a small increment noted after 60 min of stirring. Increasing the Factor VIII level to <0.01 U/ml increased the initial rate of F1+2 generation and yielded a rate of 15 pmol/ml per min at 25 min. A further increase in Factor VIII to 0.04 U/ml accelerated F1+2 generation, and with 0.08 U/ml, 60 pmol/ml per min were released between 14-16 min of incubation. However, even with this concentration, less F1+2 was generated than was seen in normal blood (Fig. 1) . per min over the first 12 min with little increment on longer incubation. Increasing the Factor VIII level to 0.008 U/ml did not change the initial rate of PF-4 release; however, after 16 min, a phase of more release ensued, similar to that noted after 8 min of incubation of normal blood (Figs. 1 and 4 Factor VIII level to 0.04 U/ml increased the initial rate of release and shortened the time to more rapid release. With a further increase to 0.08 U Factor VIII/ml, the pattern closely resembled that seen in normal blood, although with 0.08 U/ml Factor VIII, the rate of F1+2 generation was still considerably slower than normal.
DISCUSSION
The details of prothrombin conversion have been studied extensively in a purified system containing prothrombin, Factors V and Xa, and mixtures of synthetic phospholipids (17) (18) (19) . A series of recent studies have also demonstrated that prothrombin conversion occurs more rapidly on the platelet surface than in plasma (2-5). Our studies confirm and extend this previous work by documenting that platelets also accelerate prothrombin conversion in native whole blood in which coagulation proceeds in the presence of normal concentrations of various plasma substrates as well as potential inhibitors.
Our data on the relationship between platelet secretion and prothrombin cleavage differ slightly from previous studies in which radioimmunoassays were used to follow coagulation reactions in whole blood. Prior investigators have measured either the appearance of a thrombin-related neoantigen or the cleavage of fibrinopeptide A by thrombin (10, 12, 13, 15 antithrombin complexes form in plasma, albeit somewhat more slowly than the prediction derived from experiments with the purified proteins (21) . The fact that platelets undergo release when only 3-5 nM F1+2 has been cleaved suggests that some thrombin is being formed, since platelets neither bind nor react to any of the prothrombin intermediates (22) . Platelets will react to a low concentration of thrombin when it is generated on the platelet surface, but do not respond to an equivalent concentration of thrombin added to whole blood or plasma. This differential sensi- (11, 23) . This close relationship between thrombin generation and platelet release is also apparent from experiments in which Factor VIII-deficient blood is reconstituted. In general, there is a parallel relationship between the quantity of F1+2 cleaved and the Factor VIII activity of the hemophiliac blood, suggesting that F1+2 cleavage reflects Xa generation. Without any Factor VIII added, there is no cleavage of prothrombin despite prolonged incubation. Addition of a low concentration of Factor VIII results in the generation of F1+2 and the release of PF-4. However, it does not completely normalize the rate ofprothrombin cleavage. For example, the addition of sufficient Factor VIII to raise the concentration in hemophiliac blood to <0.01 U/ml, the lower limit of our assay, initiates sufficient prothrombin cleavage so that PF-4 secretion ensues after a 10-min lag. With 100-fold greater Factor VIII concentration, 0.08 U/ml, the rate and extent of F1+2 cleavage still remain less than normal, although the time to the rapid phase of secretion and the total quantity of PF-4 eventually released is identical to that seen in normal blood.
Our data also demonstrate differences between the effects of collagen and epinephrine on platelets in unanticoagulated whole blood when compared with citrated PRP. This is in keeping with previous observations from several laboratories which report that lowering calcium enhances platelet secretion (24) (25) (26) . Although both collagen and epinephrine induce secretion in citrated PRP, only collagen enhanced platelet secretion in native whole blood. Epinephrine, however, potentiated the effect of a low dose of collagen and enhanced both the secretion of PF-4 and the generation of F1+2. Since epinephrine did not induce any PF-4 secretion in Factor VIII-deficient blood in which there was no thrombin generation, it appears that secretion requires another agonist, either thrombin or collagen.
While our studies have emphasized the close relationship between prothrombin cleavage and platelet secretion, it is possible to disassociate these two events.
For example, the addition of collagen to native whole blood accelerates platelet secretion so that it occurs within the first few minutes of incubation, a time when little thrombin has been generated. Platelet secretion appears to be a direct consequence of collagen addition and not due to acceleration of intrinsic coagulation via collagen-induced Hageman factor activation, as normal PF-4 secretion occurs in Factor XII-deficient plasma (data not shown). However, the onset of the rapid phase of F1+2 generation is only accelerated by 1 or 2 min, despite the fact that maximum platelet secretion has occurred. One possible interpretation is that Xa is first generated by a series ofplatelet-independent reactions.
It then initiates more rapid prothrombin conversion as the platelets have been activated by collagen. Alternatively, Xa generation may also be enhanced by the activated platelet surface, or collagen may accelerate Xa generation by a direct interaction with Hageman factor.
The addition of PGE1 or PGI2 to whole blood clearly retards both PF-4 secretion and prothrombin activation. However, the initial phase of prothrombin activation still occurs normally, and the late phase of rapid prothrombin cleavage, although delayed, eventually occurs. These results suggest that platelet secretion per se may not acclerate early events in the coagulation sequence. However, after a threshold level of Xa and Va has been generated, independent of the platelet, the surface of the platelet may become important in catalyzing the rapid phase of prothrombin cleavage.
Our results also suggest that some prothrombin cleavage may occur independent of the platelet or, alternatively, that very few platelets are needed to support prothrombin conversion. In some preliminary experiments, we have observed that both the initial platelet-independent phase of prothrombin cleavage and the subsequent amplification process occur quite normally in blood containing as few as 6,000 platelets/ul. It is possible that alternative surfaces, such as lipoproteins or other cell surfaces, can support this initial slow phase of prothrombin conversion.
